Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc. in metadata) on October 1, 2018. The report addresses a correction regarding a Prospectus Supplement filed under Rule 424(b)(5) on the same date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a correction of a disclosure error regarding warrant terms.
Material Changes
The Company corrected an inadvertent error in its Prospectus Supplement concerning the exercise price of its public warrants:
- Incorrect Disclosure: The Prospectus Supplement erroneously stated the exercise price for 11,656,688 public warrants was $5.00 per share.
- Corrected Disclosure: The actual exercise price for one share of Common Stock is $50.00 per share, consistent with previous public filings.
Guidance, Outlook, and Risks
The filing does not contain new guidance, outlook, or management commentary on operations. The correction relates to a risk factor disclosure regarding potential dilution and stock price decline associated with future sales of common stock.
Investor Verification Checklist
- Verify the correct exercise price of the Company's public warrants is $50.00 per share, not $5.00.
- Confirm the total number of public warrants subject to this correction is 11,656,688.
- Review previous Prospectus Supplements to ensure consistency with the corrected $50.00 exercise price.